Page last updated: 2024-09-04

vatalanib and Invasiveness, Neoplasm

vatalanib has been researched along with Invasiveness, Neoplasm in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Greten, TF; Manns, MP; Plentz, RR1
Goldberg, RM; Penland, SK1
Baker, CH; Bruns, CJ; Ellis, LM; Fidler, IJ; Killion, JJ; Solorzano, CC; Wood, J1

Reviews

3 review(s) available for vatalanib and Invasiveness, Neoplasm

ArticleYear
Molecular therapy of pancreatic cancer.
    Minerva endocrinologica, 2010, Volume: 35, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Neoplasm Invasiveness; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phthalazines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A

2010
Early clinical data with small-molecule vascular endothelial growth factor tyrosine kinase receptor inhibitors.
    Clinical lung cancer, 2004, Volume: 6, Issue:2

    Topics: Angiogenesis Inhibitors; Clinical Trials, Phase I as Topic; Female; Humans; Indoles; Lung Neoplasms; Male; Neoplasm Invasiveness; Neovascularization, Pathologic; Phthalazines; Prognosis; Pyridines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Sunitinib; Treatment Outcome

2004
Combining anti-VEGF approaches with oxaliplatin in advanced colorectal cancer.
    Clinical colorectal cancer, 2004, Volume: 4 Suppl 2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Neovascularization, Pathologic; Organoplatinum Compounds; Phthalazines; Pyridines; Risk Assessment; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A

2004

Other Studies

1 other study(ies) available for vatalanib and Invasiveness, Neoplasm

ArticleYear
Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
    Cancer biotherapy & radiopharmaceuticals, 2001, Volume: 16, Issue:5

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Transplantation; Pancreatic Neoplasms; Phthalazines; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2001